BMC Cancer 2015 July 9 [Link] Ak G, Metintas S, Akarsu M, Metintas M. Abstract Background We aimed to evaluate the efficiency and safety of cis/carboplatin plus gemcitabine, which was previously used for mesothelioma but with no recorded proof of its efficiency, compared with cis/carboplatin plus pemetrexed, which is known to be effective in mesothelioma,…

Read More

Medical Oncology 2015 February [Link] de Lima VA, Sorensen JB. Abstract There is no well-defined standard third-line chemotherapy for advanced malignant pleural mesothelioma (MPM). However, combination of carboplatin, liposomised doxorubicin (Caelyx) and gemcitabine (CCG regimen) has revealed noteworthy activity when used as first-line treatment. The aim of this study is to assess efficacy and toxicity…

Read More

Medical Oncology 2014 August. [Epub 2014 June 24] [Link] Akca Z, Buyukcelik A, Cihan YB, Coskun HS, Erden A, Gunduz S, Karaca H, Mutlu H. Abstract In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens.…

Read More

Cancer Chemotherapy Pharmacology. 2014 April 1.[Epub ahead of print][Link] Arrieta O, Bacon-Fonseca L, Blake-Cerda M, Corona-Cruz J.F., Lopez-Macias D, Macedo-Perez E.O., Mendoza-Garcia V.O., Muniz-Hernandez S, Munoz-Montano W Abstract PURPOSE: Low-dose, prolonged infusion of gemcitabine has effects similar to standard doses in several cancers. We evaluated the toxicity and efficacy of low-dose gemcitabine in prolonged infusion…

Read More

Journal of Occupational Medicine and Toxicology. 2008 Dec 18;3:34. [Link] Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M. Respiratory Diseases Clinic Heckeshorn, Department of Pneumology, HELIOS Klinikum Emil von Behring, Berlin, Germany. torsten.bauer@helios-kliniken.de. Abstract Background: The aim of this study was to investigate the efficacy and safety of oxaliplatin +/- gemcitabine…

Read More

Cancer Immunology, Immunotherapy. 2009 Aug;58(8):1219-28. Epub 2008 Dec 4. [Link] van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA. National Centre for Asbestos Related Diseases, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia. robbertvdm@gmail.com Abstract Tumor cell death potentially engages with the immune…

Read More

Lung Cancer. 2009 Jun;64(3):308-13. Epub 2008 Nov 11. [Link] Lee CW, Murray N, Anderson H, Rao SC, Bishop W. BC Cancer Agency – Fraser Valley Centre, 13750 96th Avenue, Surrey, British Columbia, Canada V3V 1Z2. clee@bccancer.bc.ca Abstract Cisplatin plus pemetrexed has been standard systemic therapy for malignant pleural mesothelioma (MPM) since the landmark randomized trial…

Read More

Journal of Thoracic Oncology. 2008 Nov;3(11):1325-31. [Link] Hillerdal G, Sorensen JB, Sundström S, Riska H, Vikström A, Hjerpe A. Department of Lung Medicine and Allergology, Karolinska University Hospital, Solna, Stockholm, Sweden. gunnar.hillerdal@karolinska.se Abstract Background: Malignant pleural mesothelioma has a poor prognosis and there is limited effect of treatment. The Nordic Mesothelioma groups decided in the…

Read More